Enamine expands collaboration with Europe’s largest biopharmaceutical company

Extends multi-year agreement in drug discovery with focus on cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.

The two companies began working together in 2005 and the collaboration has grown due to the increased demand for building blocks for drug discovery. With the world’s largest stock of chemical compounds and services, Enamine has become an important supplier at Actelion. Enamine’s unique building blocks have gained recognition at Actelion and led to the signing of contracts in exclusive library synthesis for internal archive enrichment and lead compound generation.

Under the terms of the expanded agreement, scaffold compounds supplied by Actelion will be decorated with building blocks selected from the Enamine collection to generate exclusive screening compounds by Enamine. In addition, the companies have entered, under a separate contract, into a Full Time Equivalent (FTE) based research agreement, whereby Enamine will actively support Actelion’s medicinal chemistry efforts. The Enamine database of building blocks has been integrated into Actelion’s IT platform for optimizing the access, ordering and delivery time of any structure necessary for Actelion’s global research projects.

Christoph Boss, Senior Director, Chemistry Technologies and Lead Discovery at Actelion, explained: “Enamine is very well positioned among chemical CROs. Their screening compound libraries have always been highly regarded in hit-finding projects at Actelion because of their diversity and quality. The combination of Enamine’s large library of building blocks, their synthesis skills and technologies, as well as the excellent level of trust we have built over the years, makes the collaboration very attractive for Actelion. We are happy to be extending our collaboration and I look forward to reaching our next milestones.”

Michael Bossert, Head of Strategic Alliances at Enamine, said: “We have worked extensively with Actelion over the years, and we are delighted to be entering into further new areas of collaboration with such a leading pharmaceutical company. We see this as another example of Enamine’s technical and servicing expertise for optimizing and advancing our customer’s early discovery research projects. This announcement is the conclusion of another year of great successes and achievements at Enamine, ultimately working toward the launch of life changing medicines by its customers.”